Cambridge Cognition Holdings PLC (LON:COG), the specialist developer of computerised tests for detection and monitoring of neuropsychological disorders, today announced a trading update for the year ending 31 December 2017.

Join Dr. Kiri Granger, Director of Neuroscience, Cambridge Cognition and Dr. Steve Brannan, Chief Medical Officer, ‎Karuna Pharmaceuticals Inc. for a live discussion on improving clinical trial success in schizophrenia. The

How can you tell if a decision was impulsive or risky? Using the Cambridge Gambling Task to unpick how different brain regions, different drugs and different dopamine levels impact on decision-making. The Cambridge Gambling

Cambridge Cognition Holdings PLC are delighted to announce that both CANTAB Mobile and CANTAB Insight medical devices, designed for the assessment of cognitive health in clinical practice, have been approved

Social cognitive deficits have traditionally been linked with autism spectrum conditions. However, a recent paper from Cambridge Cognition suggests that deficits in social cognition are exhibited across a range of

The digital neuroscience company Cambridge Cognition Holdings plc (LON:COG), which develops and markets software products to improve brain health, has today released positive results from a pilot study to evaluate cognition

The CNS Summit takes place on the 16th-19th November in Boca Raton, Florida. The summit is a platform for fostering collaboration and innovation between the key players in cognitive technology. Cambridge Cognition will be

The 10th Clinical Trials on Alzheimer’s Disease (CTAD) conference was held in Boston last week. The event attended by world leading experts in Alzheimer’s disease clinical research focused on the earliest stages